AXIRON
LOE ApproachingNDATRANSDERMALSOLUTION, METERED
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
4/8 — Partial
AXIRON by Eli Lilly and Company is androgens, including testosterone and dihydrotestosterone (dht), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. First approved in 2010.
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AXIRON is a transdermal testosterone replacement therapy (TRT) approved in 2010 for male hypogonadism, a condition characterized by insufficient testosterone production. It delivers androgens via metered-dose solution to restore normal secondary sex characteristics, sexual function, and energy in men with low serum testosterone. The drug works by supplementing deficient testosterone and dihydrotestosterone (DHT) needed for normal male physiology.
LOE Approaching11mo to LOE
AXIRON faces imminent loss of exclusivity (LOE September 2027) with moderate competitive pressure, signaling likely reduction in dedicated brand headcount and transition toward generic defense or portfolio rotation strategies.
Mechanism of Action
androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Axiron® in Healthy Participants
Started Dec 2013
12 enrolled
Healthy Volunteers
Worked on AXIRON at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.